Skip to Content

Tabloid (thioguanine) Disease Interactions

There are 4 disease interactions with Tabloid (thioguanine):

Major

Antineoplastics (applies to Tabloid) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  4. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  5. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  6. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  7. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  8. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  9. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  10. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  11. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  12. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  13. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  14. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  15. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  16. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  17. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  18. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  19. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  20. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  21. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  22. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  23. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  24. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  25. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  27. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  28. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  29. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL.
  30. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  31. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
View all 31 references
Major

Thioguanine (applies to Tabloid) liver disease

Major Potential Hazard, Low plausibility.

Hepatotoxicity usually presented as hepatic veno-occlusive disease (hyperbilirubinemia, tender hepatomegaly, weight gain due to fluid retention, and ascites) or with signs of portal hypertension (splenomegaly, thrombocytopenia, and esophageal varices), has been reported during therapy with thioguanine. Therapy with thioguanine should be administered cautiously in patients with liver disease or predisposed to it. Patients should be instructed to immediately report any signs of hepatotoxicity such as jaundice, dark urine, upper right quadrant pain, or anorexia. Clinical monitoring of hepatic function and determination of the etiology of hepatic dysfunction is recommended.

References

  1. Kao NL, Rosenblate HJ "6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease." J Am Acad Dermatol 28 (1993): 1017-8
  2. Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW "Hepatic veno-occlusive disease caused by 6-thioguanine." Ann Intern Med 96 (1982): 58-60
  3. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
  4. Griner PF, Elbadawi A, Packman CH "Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases." Ann Intern Med 85 (1976): 578-82
  5. Larrey D, Freneaux E, Berson A, Babany G, Degott C, Valla D, Pessayre D, Benhamou JP "Peliosis hepatis induced by 6-thioguanine administration." Gut 29 (1988): 1265-9
  6. Satti MB, Weinbren K, Gordon-Smith EC "6-thioguanine as a cause of toxic veno-occlusive disease of the liver." J Clin Pathol 35 (1982): 1086-91
View all 6 references
Major

Thioguanine (applies to Tabloid) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bleeding, Fever, Bone Marrow Depression/Low Blood Counts

The most consistent, dose-related toxicity of thioguanine is bone marrow suppression. This may be manifested by anemia, leukopenia, thrombocytopenia, or any combination of these. However, any one of these findings may also reflect progression of the underlying disease. Since thioguanine may have a delayed effect, it is important to withdraw the medication temporarily at the first sign of an abnormally large fall in any of the formed elements of the blood. Therapy with thioguanine should be administered cautiously in patients with myelosuppression. It is recommended that evaluation of the hemoglobin concentration or hematocrit, total white blood cell count and differential count, and quantitative platelet count be obtained frequently while the patient is on thioguanine therapy.

References

  1. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.
Major

Thioguanine (applies to Tabloid) TMPT enzyme deficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Enzymopathy (Unspecified)

Thioguanine is closely related structurally and functionally to mercaptopurine. A rare deficiency in the enzyme thiopurine methyltransferase (TMPT) results in an increased sensitivity to the myelosuppressive effects of both drugs causing rapid bone marrow suppression following initial mercaptopurine or thioguanine administration. Therapy with thioguanine or mercaptopurine should be administered cautiously and at a reduced dose in patients with TMPT deficiency.

References

  1. "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.

Tabloid (thioguanine) drug interactions

There are 435 drug interactions with Tabloid (thioguanine)

Tabloid (thioguanine) alcohol/food interactions

There is 1 alcohol/food interaction with Tabloid (thioguanine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.